title: Early and prolonged response to pazopanib in a patient with multiple metastases from renal cell carcinoma: a case report.
abstract: OBJECTIVE
  In recent years, targeted agents have replaced cytokine therapy as the standard of care for patients with metastatic renal cell carcinoma.
  
  
  METHODS
  We report a patient with multiple metastases from renal cell carcinoma treated with cytoreductive surgery and pazopanib.
  
  
  CONCLUSIONS
  The treatment resulted in an early and prolonged response, without toxicity.
authors: Elisa
authors: E
authors: Biasco
authors: Andrea
authors: A
authors: Antonuzzo
authors: Claudia
authors: C
authors: Cianci
authors: Lisa
authors: L
authors: Derosa
authors: Riccardo
authors: R
authors: Marconcini
authors: Azzurra
authors: A
authors: Farnesi
authors: Luca
authors: L
authors: Galli
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000188:drug therapy / Q000556:secondary; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D003964:Diaphragm; D006801:Humans; D007191:Indazoles; D060828:Induction Chemotherapy; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009379:Neoplasms, Muscle Tissue / Q000188:drug therapy / Q000556:secondary; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib